Holen Sie sich die Stockscreener-App
46.97
1.64%
0.76
Handel nachbörslich:
46.97
Enliven Therapeutics Inc Aktie (ELVN) Neueste Nachrichten
Director Jeffrey Garland proposes selling 13,000 Enliven Therapeutics (NASDAQ: ELVN) shares. - Stock Titan
ELVN Initiated Coverage by JP Morgan -- Rating Set to Overweight - GuruFocus
JPMorgan Initiates Enliven Therapeutics at Overweight With $75 Price Target - marketscreener.com
Enliven Therapeutics stock initiated at Overweight by JPMorgan - Investing.com Canada
Understanding the Setup: (ELVN) and Scalable Risk - Stock Traders Daily
ELVN Stock On Track For Best Week Since March Following FDA-Aligned Path For Cancer Drug Development - Stocktwits
Enliven Therapeutics CMO Helen Collins sells $251k in shares By Investing.com - Investing.com South Africa
Enliven Therapeutics CFO Benjamin Hohl sells $303,003 in stock By Investing.com - Investing.com South Africa
Enliven Therapeutics CFO Benjamin Hohl sells $303,003 in stock - Investing.com
Enliven Therapeutics CFO Completes Stock Option Exercise and Multi-Tranche Stock Sales - kalkinemedia.com
Enliven Therapeutics Insider Sold Shares Worth $251,754, According to a Recent SEC Filing - marketscreener.com
Enliven Therapeutics Insider Sold Shares Worth $303,003, According to a Recent SEC Filing - Yahoo Finance
Enliven Therapeutics (ELVN) CFO exercises options, sells 6,018 shares - Stock Titan
Enliven Therapeutics, Inc. (ELVN) Stock Analysis: Biotech Innovator with a 47% Upside Potential - DirectorsTalk Interviews
Enliven Therapeutics (ELVN) officer lines up new stock sale - Stock Titan
Transcript : Enliven Therapeutics, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-16-2026 11 - marketscreener.com
ELVN: ELVN-001 targets a $16B global CML market with best-in-class efficacy and strong clinical momentum - TradingView
Enliven Therapeutics at Morgan Stanley conference: cash, trials and CML By Investing.com - Investing.com Canada
ELVN: ELVN-001 targets major CML market segments with strong clinical and commercial differentiation - TradingView
(ELVN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight - GlobeNewswire Inc.
Planned stock sale at Enliven Therapeutics (NASDAQ: ELVN) tops the million-dollar mark - Stock Titan
Enliven's Morgan Stanley conference chat will be webcast Sept. 16 - Stock Titan
Enliven Therapeutics to Present at Upcoming Investor Conferences - PR Newswire
Enliven Therapeutics: A Clean Active-Site TKI Could Redefine CML Sequencing (NASDAQ:ELVN) - Seeking Alpha
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting - PR Newswire
Discipline and Rules-Based Execution in ELVN Response - Stock Traders Daily
Enliven Therapeutics Presents ELVN-001 Data at SOHO Annual Meeting - Intellectia AI
Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Argenx Se (ARGX) - The Globe and Mail
Enliven Therapeutics Inc. (NASDAQ: ELVN) Share Price, ELVN Stock News, ELVN Share Price & Updates - kalkine.ca
Enliven (ELVN) Earnings Snapshot: EPS Falls Short of Its Estimate in the Reported Period; Share Response: The Stock Records a 0.79% Decrease on the DayProfit Cycle Analysis - vinanet.vn
Handelsbanken Fonder AB Buys New Shares in Enliven Therapeutics, Inc. $ELVN - MarketBeat
Enliven Therapeutics CFO Benjamin Hohl Executes Two Stock Sales on August 17 Under 10b5-1 Plan - Kalkine Media
Benjamin Hohl Sells 6,018 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock - MarketBeat
Enliven (NASDAQ: ELVN) CFO sells 6,018 shares in 10b5-1 plan - Stock Titan
Enliven Therapeutics (ELVN) CMO exercises options, sells stock - Stock Titan
Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says - Sahm
Barclays Initiates Enliven Therapeutics at Overweight With $78 Price Target - Moomoo
Enliven Therapeutics CMO Helen Louise Collins Executes Stock Option and Sells 5,000 Shares Under 10b5-1 Plan - Kalkine Media
Enliven Therapeutics, Inc. /US/ Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
What's Going On With Enliven Therapeutics Stock Tuesday?Enliven Therapeutics (NASDAQ:ELVN) - Benzinga
Enliven a new outperform at Barclays on potential of CML asset - Seeking Alpha
Enliven Therapeutics (NASDAQ:ELVN) Now Covered by Analysts at William Blair - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Now Covered by Barclays - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Given New $73.00 Price Target at Mizuho - MarketBeat
Barclays initiates Enliven Therapeutics stock at Overweight, $78 PT By Investing.com - Investing.com Canada
William Blair Initiates Enliven Therapeutics at Outperform - marketscreener.com
William Blair initiates Enliven Therapeutics stock with outperform rating By Investing.com - Investing.com Canada
261,344 Shares in Enliven Therapeutics, Inc. $ELVN Acquired by TimesSquare Capital Management LLC - MarketBeat
Mizuho Raises Price Target on Enliven Therapeutics to $73 From $62, Keeps Outperform Rating - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Stifel Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $82 - Moomoo
Tema ETFs LLC Grows Stake in Enliven Therapeutics, Inc. $ELVN - MarketBeat
FMR LLC Boosts Stake in Enliven Therapeutics Inc (ELVN) with Str - GuruFocus
Janus Henderson Group PLC Sells 1,660,724 Shares of Enliven Therapeutics, Inc. $ELVN - MarketBeat
Assenagon Asset Management S.A. Makes New Investment in Enliven Therapeutics, Inc. $ELVN - MarketBeat
Enliven Therapeutics (ELVN) Pulls Back 1.44% to $58.56 as Support HoldsIsland Reversal - dars.gov.et
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):